FNCH
Income statement / Annual
Last year (2024), Finch Therapeutics Group, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Finch Therapeutics Group, Inc.'s net income was -$13.88 M.
See Finch Therapeutics Group, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$107.00 K |
$861.00 K |
$18.53 M |
$7.72 M |
$10.15 M |
| Cost of Revenue |
$174.00 K
|
$1.52 M
|
$5.51 M
|
$57.28 M
|
$33.14 M
|
$314.00 K
|
| Gross Profit |
-$174.00 K
|
-$1.41 M
|
-$4.65 M
|
-$38.75 M
|
-$25.43 M
|
$9.84 M
|
| Gross Profit Ratio |
0
|
-13.21
|
-5.4
|
-2.09
|
-3.29
|
0.97
|
| Research and Development Expenses |
$0.00
|
$7.20 M
|
$52.86 M
|
$57.28 M
|
$33.14 M
|
$23.54 M
|
| General & Administrative Expenses |
$0.00
|
$26.91 M
|
$38.09 M
|
$21.24 M
|
$14.01 M
|
$7.44 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$18.69 M
|
$26.91 M
|
$36.19 M
|
$21.24 M
|
$14.01 M
|
$7.44 M
|
| Other Expenses |
$0.00
|
-$1.52 M
|
$1.42 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$18.69 M
|
$32.59 M
|
$90.47 M
|
$78.52 M
|
$47.16 M
|
$30.98 M
|
| Cost And Expenses |
$18.86 M
|
$34.11 M
|
$95.98 M
|
$78.52 M
|
$47.16 M
|
$31.30 M
|
| Interest Income |
$796.00 K
|
$1.57 M
|
$252.00 K
|
$22.00 K
|
$106.00 K
|
$488.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$174.00 K
|
$1.52 M
|
$5.51 M
|
$2.30 M
|
$790.00 K
|
$482.00 K
|
| EBITDA |
-$13.70 M |
-$32.48 M |
-$82.69 M |
-$57.68 M |
-$38.65 M |
-$20.66 M |
| EBITDA Ratio |
0
|
-303.57
|
-96.04
|
-3.11
|
-5.01
|
-2.03
|
| Operating Income Ratio |
0
|
-317.78
|
-110.48
|
-3.24
|
-5.11
|
-2.08
|
| Total Other Income/Expenses Net |
$4.98 M
|
-$44.21 M
|
-$19.53 M
|
$1.83 M
|
$95.00 K
|
$388.00 K
|
| Income Before Tax |
-$13.88 M
|
-$78.22 M
|
-$114.65 M
|
-$58.16 M
|
-$39.34 M
|
-$20.75 M
|
| Income Before Tax Ratio |
0
|
-730.98
|
-133.15
|
-3.14
|
-5.1
|
-2.04
|
| Income Tax Expense |
$0.00
|
-$3.46 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$13.88 M
|
-$74.75 M
|
-$114.65 M
|
-$58.16 M
|
-$39.25 M
|
-$20.75 M
|
| Net Income Ratio |
0
|
-698.64
|
-133.15
|
-3.14
|
-5.08
|
-2.04
|
| EPS |
-8.64 |
-46.59 |
-72.12 |
-36.72 |
-24.39 |
-12.68 |
| EPS Diluted |
-8.64 |
-46.59 |
-72.12 |
-36.72 |
-24.39 |
-12.68 |
| Weighted Average Shares Out |
$1.61 M
|
$1.60 M
|
$1.59 M
|
$1.58 M
|
$1.61 M
|
$1.61 M
|
| Weighted Average Shares Out Diluted |
$1.61 M
|
$1.60 M
|
$1.59 M
|
$1.58 M
|
$1.61 M
|
$1.61 M
|
| Link |
|
|
|
|
|
|
